MCL

Oncology

17 drugs in development·13 companies·3 clinical trials

Drug Pipeline by Phase

Approved(6)

Drug	Company
ayvakit	Blueprint Medicines Corp (BPMC)
brukinsa	BeOne Medicines Ltd. (ONC)
clonoSEQ	Adaptive Biotechnologies Corp (ADPT)
jaypirca	LOXO ONCOLOGY, INC. (LOXO)
Jaypirca	ELI LILLY & Co (LLY)
Jaypirca®	ELI LILLY & Co (LLY)

Phase 3(6)

Drug	Company
kte-c19	Kite Pharma, Inc. (KITE)
Orelabrutinib	Merus N.V. (MRUS)
Rocbrutinib	Merus N.V. (MRUS)
Venetoclax	ASTRAZENECA PLC (AZN)
Zanubrutinib	Merus N.V. (MRUS)
zilovertamab	Oncternal Therapeutics, Inc. (ONCT)

Phase 2(3)

Drug	Company
ACP-196	CYTOKINETICS INC (CYTK)
rocbrutinib	NYMOX PHARMACEUTICAL CORP (NYMXF)
Venetoclax	CYTOKINETICS INC (CYTK)

Phase 1(1)

Drug	Company
zelebrudomide	Nurix Therapeutics, Inc. (NRIX)

Phase 1/Phase 2(1)

Drug	Company
abexinostat	XYNOMIC PHARMACEUTICALS HOLDINGS, INC. (BCACU)

BioSniper tracks 17 drugs in development for MCL across 13 companies.

There are 3 clinical trials targeting MCL tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.